Repurposing CD8(+) T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?

The COVID-19 pandemic has afflicted most countries on the planet. As a result, immunity against SARS-CoV-2, induced via natural infections or imminent vaccinations, is expected to develop in a large fraction of the global population. Here, we propose to exploit SARS-CoV-2-specific CD8(+) T cells for...

Descripción completa

Detalles Bibliográficos
Autores principales: Gujar, Shashi, Pol, Jonathan G., Kim, Youra, Kroemer, Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Point-of-View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458627/
https://www.ncbi.nlm.nih.gov/pubmed/32923158
http://dx.doi.org/10.1080/2162402X.2020.1794424
Descripción
Sumario:The COVID-19 pandemic has afflicted most countries on the planet. As a result, immunity against SARS-CoV-2, induced via natural infections or imminent vaccinations, is expected to develop in a large fraction of the global population. Here, we propose to exploit SARS-CoV-2-specific CD8(+) T cells for cancer immunotherapy strategies.

Ejemplares similares